NDV-HXP-S (known as ButanVac[2][3] or ADAPTCOV[4] in Brazil, COVIVAC[5] in Vietnam, HXP-GPOVac[6] in Thailand, Patria[7] in Mexico) is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.

[11] Its development was coordinated by the PATH Center for Vaccine Innovation and Access, and UT Austin and ISMMS have arranged royalty-free licensing agreements with labs and corporations in 80 countries.

In Brazil, on March 26, 2021, the Butantan Institute announced it would seek to begin clinical trials.

In Thailand the Government Pharmaceutical Organization is conducting a trial in coordination with Mahidol University.

[14] The Butantan trials were discontinued at phase II in late 2023 due to lack of efficacy.